As previously reported, Canaccord analyst Mark Massaro downgraded Hologic to Hold from Buy and lowered his price target on the shares to $39 from $48. In a pre-open research note, the analyst said Hologic "has started off on the wrong foot this year, a clear disappointment," and it is unclear to him that resetting the guide changes the fact that Cynosure does not appear to have a near-term catalyst to stabilize the segment, nor does he have conviction it can achieve its goal of double-digit growth anytime soon. Massaro also removed Hologic as one of his top 5 picks for 2018.